Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety of a single dose of RG2077 in patients
with systemic lupus erythematosus (SLE) who are currently receiving cyclophosphamide. This
study will also determine if RG2077 is effective in decreasing disease activity in these
patients.
Study hypothesis: CTLA4-Ig mediates a T cell costimulatory blockade that effectively induces
an antigen-specific nonresponsiveness in T cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)